Published in Hum Mol Genet on August 16, 2012
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis (2015) 0.97
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem (2013) 0.97
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci (2013) 0.95
Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation. J Neurosci (2013) 0.93
Wnt your brain be inflamed? Yes, it Wnt! Trends Mol Med (2013) 0.93
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci (2014) 0.89
Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases (2013) 0.87
Cellular processes associated with LRRK2 function and dysfunction. FEBS J (2015) 0.86
Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease. Stem Cells (2014) 0.86
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. Neuroscience (2014) 0.85
Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease. J Mol Cell Biol (2014) 0.85
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol Dis (2013) 0.83
LRRK2: an éminence grise of Wnt-mediated neurogenesis? Front Cell Neurosci (2013) 0.83
The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol (2013) 0.82
LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis (2017) 0.77
Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. Front Mol Neurosci (2016) 0.76
ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease. Biochim Biophys Acta (2013) 0.76
Back to the tubule: microtubule dynamics in Parkinson's disease. Cell Mol Life Sci (2016) 0.75
The Kinome of Pacific Oyster Crassostrea gigas, Its Expression during Development and in Response to Environmental Factors. PLoS One (2016) 0.75
Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. Mol Neurodegener (2017) 0.75
The Presynaptic Microtubule Cytoskeleton in Physiological and Pathological Conditions: Lessons from Drosophila Fragile X Syndrome and Hereditary Spastic Paraplegias. Front Mol Neurosci (2016) 0.75
A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Mol Neurodegener (2017) 0.75
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development (2001) 9.00
Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A (2003) 7.60
Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol (2003) 6.60
Towards an integrated view of Wnt signaling in development. Development (2009) 6.07
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Differential recruitment of Dishevelled provides signaling specificity in the planar cell polarity and Wingless signaling pathways. Genes Dev (1998) 4.51
Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell (2000) 4.35
Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell (2010) 4.19
Amino terminal myristylation of the protein kinase p60src, a retroviral transforming protein. Science (1985) 3.97
Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature (1990) 3.92
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Mouse Wnt genes exhibit discrete domains of expression in the early embryonic CNS and limb buds. Development (1993) 3.66
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci (2009) 2.69
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett (1992) 2.52
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Differential expression of the HMG box factors TCF-1 and LEF-1 during murine embryogenesis. Development (1993) 2.22
Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci U S A (2003) 2.14
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci (2002) 2.08
A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol (2004) 1.90
NMDA-receptor activation induces calpain-mediated beta-catenin cleavages for triggering gene expression. Neuron (2007) 1.87
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science (2008) 1.81
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain. Cell Signal (2005) 1.74
Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem (2007) 1.70
Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol (2000) 1.68
The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol (1991) 1.65
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Crude subcellular fractionation of cultured mammalian cell lines. BMC Res Notes (2009) 1.56
Generation of mice with a conditional null allele for Wntless. Genesis (2010) 1.55
Wnt regulates axon behavior through changes in microtubule growth directionality: a new role for adenomatous polyposis coli. J Neurosci (2008) 1.50
Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons. J Biol Chem (2007) 1.47
Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.46
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses. Proc Natl Acad Sci U S A (2010) 1.39
The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther (2008) 1.38
Neurite outgrowth involves adenomatous polyposis coli protein and beta-catenin. J Cell Sci (2005) 1.34
Mendelian forms of Parkinson's disease. Biochim Biophys Acta (2009) 1.33
Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca²⁺/Calmodulin-dependent protein kinase II. Proc Natl Acad Sci U S A (2011) 1.30
Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest (2008) 1.29
Purified Wnt-5a increases differentiation of midbrain dopaminergic cells and dishevelled phosphorylation. J Neurochem (2005) 1.24
LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci (2010) 1.23
Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet (2009) 1.22
Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Commun (2011) 1.22
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem (2006) 1.18
Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis (2010) 1.17
A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener (2011) 1.13
Regulation of NMDA-receptor synaptic transmission by Wnt signaling. J Neurosci (2011) 1.12
LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J (2009) 1.11
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol Cell Neurosci (2005) 1.09
Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res (2008) 1.08
Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J Neurochem (2007) 1.04
Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem (2009) 1.04
RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics (2007) 1.03
Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun (2009) 1.02
LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol (2011) 1.01
Canonical Wnt3a modulates intracellular calcium and enhances excitatory neurotransmission in hippocampal neurons. J Biol Chem (2010) 1.00
LEF1/beta-catenin complex regulates transcription of the Cav3.1 calcium channel gene (Cacna1g) in thalamic neurons of the adult brain. J Neurosci (2010) 0.98
Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegener (2009) 0.98
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord (2010) 0.96
c-Jun N-terminal kinase (JNK) cooperates with Gsk3beta to regulate Dishevelled-mediated microtubule stability. BMC Cell Biol (2007) 0.96
Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics (2007) 0.96
Dynamic temporal and cell type-specific expression of Wnt signaling components in the developing midbrain. Exp Cell Res (2006) 0.96
Delayed dopaminergic neuron differentiation in Lrp6 mutant mice. Dev Dyn (2010) 0.90
Effects of age and gender on WNT gene expression in human bone marrow stromal cells. J Cell Biochem (2009) 0.88
The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol (2009) 0.87
A coated vesicle-associated kinase of 104 kDa (CVAK104) induces lysosomal degradation of frizzled 5 (Fzd5). J Biol Chem (2009) 0.87
Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett (2007) 0.87
Novel regulatory mechanism of canonical Wnt signaling by dopamine D2 receptor through direct interaction with beta-catenin. Mol Pharmacol (2011) 0.81
Wnt-pathway activation during the early stage of neurodegeneration in FTDP-17 mice. Neurobiol Aging (2007) 0.80
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol (2007) 4.60
GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 3.38
Highly effective SNP-based association mapping and management of recessive defects in livestock. Nat Genet (2008) 2.68
Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron (2009) 2.44
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet (2006) 1.49
The genetics of hyperekplexia: more than startle! Trends Genet (2008) 1.49
Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice. EMBO J (2007) 1.49
Complex role of collybistin and gephyrin in GABAA receptor clustering. J Biol Chem (2010) 1.40
TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Hum Mol Genet (2010) 1.35
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci (2010) 1.33
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation. Hum Mutat (2009) 1.32
The residence time of GABA(A)Rs at inhibitory synapses is determined by direct binding of the receptor α1 subunit to gephyrin. J Neurosci (2011) 1.25
Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet (2009) 1.22
Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains to the glycine receptor, and mutation analysis in hyperekplexia. J Biol Chem (2003) 1.17
The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochem Soc Trans (2012) 1.04
Collybistin splice variants differentially interact with gephyrin and Cdc42 to regulate gephyrin clustering at GABAergic synapses. J Cell Sci (2011) 1.03
The glycinergic system in human startle disease: a genetic screening approach. Front Mol Neurosci (2010) 1.02
Diversity of glycine receptors in the mouse retina: localization of the alpha3 subunit. J Comp Neurol (2003) 1.01
LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol (2011) 1.01
Molecular basis of the γ-aminobutyric acid A receptor α3 subunit interaction with the clustering protein gephyrin. J Biol Chem (2011) 1.00
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem (2013) 0.97
Multifunctional basic motif in the glycine receptor intracellular domain induces subunit-specific sorting. J Biol Chem (2009) 0.96
The cell adhesion molecule neurofascin stabilizes axo-axonic GABAergic terminals at the axon initial segment. J Biol Chem (2011) 0.95
Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem (2012) 0.93
Novel missense mutations in the glycine receptor β subunit gene (GLRB) in startle disease. Neurobiol Dis (2012) 0.92
Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol Dis (2005) 0.92
Differential regulation of the postsynaptic clustering of γ-aminobutyric acid type A (GABAA) receptors by collybistin isoforms. J Biol Chem (2011) 0.90
An N-terminal histidine regulates Zn(2+) inhibition on the murine GABA(A) receptor beta3 subunit. Br J Pharmacol (2002) 0.89
A critical role for glycine transporters in hyperexcitability disorders. Front Mol Neurosci (2008) 0.84
LRRK2: an éminence grise of Wnt-mediated neurogenesis? Front Cell Neurosci (2013) 0.83
The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol (2013) 0.82
Frontal lobe dysfunction in sporadic hyperekplexia--case study and literature review. J Neurol (2004) 0.78
Selective localization of collybistin at a subset of inhibitory synapses in brain circuits. J Comp Neurol (2012) 0.77